• Ferritin Hybrid Particles for Dual-Antigen Vaccines

  2026-10-06

  Song and colleagues describe a ferritin-based hybrid protein particle that presents influenza A M2e and SARS-CoV-2 S-protein tandem epitopes within one recombinant platform. In mice, the hybrid particle produced stronger antigen-specific responses than antigen-only or corresponding single-antigen ferritin constructs, while functional assays supported activity against a SARS-CoV-2 pseudovirus model and M2e-bearing cells.

• Influenza Hemagglutinin (HA) Peptide: Evidence Guide

  2026-10-06

  A source-grounded guide to how the HA tag peptide works, what the available evidence supports, and where claims about detection, elution, and protein purification remain limited.

• Brazilin, Ferroptosis, and the p53/SLC7A11/GPX4 Axis

  2026-10-05

  A 2024 study reports that brazilin suppresses 4T1 breast cancer cell growth while producing biochemical, mitochondrial, and protein-expression changes consistent with ferroptosis. Its central contribution is the proposed connection between brazilin activity and the p53/SLC7A11/GPX4 pathway, although the single-cell-line, in vitro design limits causal and translational conclusions.

• Recombinant Human EGF in Cancer Stemness Research

  2026-10-05

  Epidermal Growth Factor is a biologically plausible signaling input for studying proliferation, differentiation, and glioblastoma cell-state behavior, but current supplied evidence does not directly show that recombinant human EGF drives the spheroid findings reported by Chen et al. This overview separates supplier-reported product characteristics from published assay findings and defines the limits of interpreting spheroid formation as a stemness measure.

• Ferrostatin-1 in Ferroptosis Research: Evidence Overview

  2026-10-04

  Ferrostatin-1 (Fer-1) is a research compound used to investigate ferroptosis, an iron-dependent form of regulated cell death involving oxidative damage to membrane lipids. This overview places Fer-1 in context, examines its reported relevance to cancer biology research and ferroptosis assays, and evaluates findings from a 2022 epithelial ovarian cancer study involving the ADAMTS9-AS1–miR-587–SLC7A11 axis. The available evidence supports mechanistic use as a pharmacological probe, but does not establish clinical efficacy or prove that Fer-1 directly regulates this molecular pathway.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-10-03

  Oliveira and colleagues reported that selected naturally occurring angiotensin peptides increase the apparent binding of SARS-CoV-2 spike protein to host receptors, with the strongest effects associated with shorter or structurally modified peptides. The work provides a biochemical structure–activity framework, while its implications for viral entry, COVID-19 pathogenesis, and treatment remain investigational.

• Dextrose in Hypoxia-Driven Immunometabolism

  2026-10-02

  Learn how Dextrose (D-glucose) enables controlled tumor–immune nutrient-competition models under hypoxia. This practical guide combines stock preparation, oxygen-controlled workflows, assay design, and troubleshooting for reproducible glucose metabolism research.

• Vidarabine Monohydrate: Assay Design Guide

  2026-10-01

  Vidarabine monohydrate is an adenosine-mimetic antiviral research compound for investigating viral DNA synthesis and replication. This guide combines molecular mechanism, solvent planning, assay controls, and a translationally cautious lesson from a recent interaction-screening study.

• 2-Hydroxypropyl-β-cyclodextrin Protocol

  2026-10-01

  2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide used to screen and formulate poorly water-soluble hydrophobic compounds, especially aromatic or phenyl-containing molecules, through inclusion complex formation. This guide covers dossier values and a practical solubility workflow; it should be treated as a research excipient rather than evidence of therapeutic efficacy or clinical bioavailability.

• Firefly Luciferase mRNA: A Translation Control

  2026-09-30

  Firefly Luciferase mRNA (ARCA, 5-moUTP) can function as more than a bright reporter: it provides a practical bridge between controlled translation studies and reproducible cellular assays. This guide explains how cap chemistry, 5-methoxyuridine, poly(A) design, and experimental context shape the signal.

• Trichostatin A (TSA): Practical HDAC Workflows

  2026-09-30

  Trichostatin A (TSA) converts HDAC biology into measurable assays for chromatin acetylation, cancer-cell phenotypes, and regeneration research. This practical guide connects dose planning, temporal sampling, and troubleshooting with findings from axolotl limb regeneration and breast cancer models.

• Vidarabine Monohydrate: From Mechanism to Translation

  2026-09-29

  A thought-leadership guide to using Vidarabine monohydrate as a mechanistically grounded antiviral research compound, with practical advice on assay design, translational rigor, solubility, and the responsible use of cross-domain screening insights.

• LTI6426 Enhances Panobinostat in Multiple Myeloma

  2026-09-29

  The reference study shows that the orally bioavailable PDI inhibitor LTI6426 can substantially improve low-dose panobinostat activity in multiple myeloma models, including a proteasome inhibitor-resistant setting. Its main mechanistic contribution is the identification of ATF3, DDIT3/CHOP, and DNAJB1 as coordinated endoplasmic-reticulum-stress response markers that may guide pharmacodynamic studies.

• Morin C5297: Mechanism, Evidence, and Workflows

  2026-09-28

  Morin is a natural flavonoid identified as 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one. Its reported research uses include oxidative-stress, inflammation, adenosine 5′-monophosphate deaminase, mitochondrial, fluorescence, diabetes, cancer, and neurodegeneration studies, but product bioactivity data do not establish clinical efficacy.

• Bortezomib (PS-341) in Proteasome Assays

  2026-09-28

  Use Bortezomib (PS-341) to test whether proteasomal degradation links protein ubiquitination to cell-state changes—then pair target-protein measurements with viability and apoptosis readouts. A practical workflow connects the MAPK10–KRT16 findings in NSCLC to carefully controlled inhibitor experiments without treating the paper as evidence that it tested bortezomib.

8124 records 1/542 page Next 12345 下5页 Last page